Educational content on VJRegenMed is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2020 | Results of a site-manufactured anti-CD19 CAR-T in nHL

Marcos de Lima • 24 Aug 2020
SOHO 2020
Lymphoma Non-Hodgkin Lymphoma

Marcos de Lima, MD, of UH Cleveland Medical Center, Cleveland, OH, discusses the results of a study evaluating a second-generation anti-CD19 CAR-T construct consisting of a 4-1BB co-stimulatory domain in heavily pre-treated non-Hodgkin lymphoma (nHL) patients. This interview was recorded via an online conference call with The Video Journal of Regenerative Medicine (VJRegenMed).

More from Marcos de Lima

1:11
Point-of-care CAR T-cells
Marcos de Lima • 16 Sep 2020
5:18
Outlook on the current CAR-T climate
Marcos de Lima • 24 Aug 2020

Related Videos

3:19
Safety and efficacy of LV20.19 CAR-T therapy in Richter's transformation and R/R MCL
Nirav Shah • 15 Feb 2023
3:02
Phase I study of rapcabtagene autoleucel in patients with R/R DLBCL
Nirav Shah • 15 Feb 2023
2:17
The importance of managing hematologic toxicity associated with CAR-T therapy
Marion Subklewe • 10 Feb 2023
5:36
Investigating real-world outcomes of patients with R/R LBCL after CD19 CAR-T cell therapy
Veit Buecklein • 9 Dec 2022
The content of VJRegenMed is intended for healthcare professionals